Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-26
2011-07-26
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S019300, C514S002400, C514S020200
Reexamination Certificate
active
07985735
ABSTRACT:
Smac mimetics that inhibit IAPs.
REFERENCES:
patent: 3832253 (1974-08-01), DiPalma et al.
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4278793 (1981-07-01), Durckheimer et al.
patent: 4452775 (1984-06-01), Kent
patent: 4667014 (1987-05-01), Nestor, Jr. et al.
patent: 4748034 (1988-05-01), deRham
patent: 5075109 (1991-12-01), Tice et al.
patent: 5239660 (1993-08-01), Ooi
patent: 5660811 (1997-08-01), Mills
patent: 5766572 (1998-06-01), Hasegawa et al.
patent: 6110691 (2000-08-01), Wang et al.
patent: 6133437 (2000-10-01), Korneluk et al.
patent: 6187557 (2001-02-01), Rothe et al.
patent: 6338835 (2002-01-01), Shochat et al.
patent: 6608026 (2003-08-01), Wang et al.
patent: 6911426 (2005-06-01), Reed et al.
patent: 6992063 (2006-01-01), Shi et al.
patent: 7217688 (2007-05-01), Reed et al.
patent: 7244851 (2007-07-01), Cohen et al.
patent: 7309792 (2007-12-01), Harran et al.
patent: 7517906 (2009-04-01), Condon et al.
patent: 7579320 (2009-08-01), Boudreault et al.
patent: 7589118 (2009-09-01), Laurent et al.
patent: 2002/0132786 (2002-09-01), Alnemri
patent: 2002/0160975 (2002-10-01), Alnemri
patent: 2002/0177557 (2002-11-01), Shi
patent: 2004/0054148 (2004-03-01), Alnemri et al.
patent: 2005/0197403 (2005-09-01), Harran et al.
patent: 2005/0234042 (2005-10-01), Palermo et al.
patent: 2005/0261203 (2005-11-01), Cohen et al.
patent: 2006/0014700 (2006-01-01), Cohen et al.
patent: 2006/0025347 (2006-02-01), Condon et al.
patent: 2006/0052311 (2006-03-01), Sharma et al.
patent: 2006/0128632 (2006-06-01), Sharma et al.
patent: 2006/0167066 (2006-07-01), Cohen et al.
patent: 2006/0194741 (2006-08-01), Condon et al.
patent: 2006/0258581 (2006-11-01), Reed et al.
patent: 2006/0264379 (2006-11-01), Jarvis et al.
patent: 2007/0003535 (2007-01-01), Reed et al.
patent: 2007/0042428 (2007-02-01), Springs et al.
patent: 2007/0093428 (2007-04-01), Laurent
patent: 2007/0093429 (2007-04-01), Laurent et al.
patent: 2008/0089896 (2008-04-01), Wang et al.
patent: 2009/0005411 (2009-01-01), Jensen et al.
patent: 2009/0104151 (2009-04-01), Hanson et al.
patent: 2009/0123480 (2009-05-01), Wang et al.
patent: 2009/0142334 (2009-06-01), Korneluk et al.
patent: 2009/0192140 (2009-07-01), Laurent et al.
patent: 2009/0221630 (2009-09-01), Koehler et al.
patent: 2010/0130539 (2010-05-01), Koehler
patent: WO 99/15657 (1999-04-01), None
patent: WO 02/16418 (2002-02-01), None
patent: WO 02/26775 (2002-04-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 02/096930 (2002-12-01), None
patent: WO 03/018014 (2003-03-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 2004/007529 (2004-01-01), None
patent: WO 2004/072105 (2004-08-01), None
patent: WO 2005/069888 (2005-08-01), None
patent: WO 2005/069894 (2005-08-01), None
patent: WO 2005/078989 (2005-08-01), None
patent: WO 2005074989 (2005-08-01), None
patent: WO 2005/084317 (2005-09-01), None
patent: WO 2005/094818 (2005-10-01), None
patent: WO 2005/097791 (2005-10-01), None
patent: WO 2006/010118 (2006-01-01), None
patent: WO 2006/014361 (2006-02-01), None
patent: WO 2006/017295 (2006-02-01), None
patent: WO 2006/020060 (2006-02-01), None
patent: WO 2006/069063 (2006-06-01), None
patent: WO 2006/091972 (2006-08-01), None
patent: WO 2006/122408 (2006-11-01), None
patent: WO 2006/128455 (2006-12-01), None
patent: WO 2006/133147 (2006-12-01), None
patent: WO 2007/021825 (2007-02-01), None
patent: WO 2007/101347 (2007-09-01), None
patent: WO 2007/106192 (2007-09-01), None
patent: WO 2007101347 (2007-09-01), None
patent: WO 2007/130626 (2007-11-01), None
patent: WO 2007/136921 (2007-11-01), None
patent: WO 2008/016893 (2008-02-01), None
patent: WO 2008057172 (2008-05-01), None
patent: WO 2008134679 (2008-11-01), None
Kohli et al., SMAC/Diablo-dependent apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs) in colon cancer cells, 2004, PNAS 101(48):16897-16902.
Ripka et al., Peptidomimetic design, 1998, Curr. Op. Chem. Biol. 2:441-452.
Hruby et al., Synthesis of oligopeptide and peptidomimetic libraries, 1997, Curr. Op. in Chem. Biol. 1:114-119.
Hruby et al., Conformational and Topographical Considerations in Designing Agonist Peptidomimetics from Peptide Leads, 2000, Curr. Med. Chem. 7(9):945-970.
Nikolovska-Coleska et al., Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization, 2004, Anal. Biochem. 332:261-273.
Macor et al., The Synthesis of a Conformationally Restricted Analog of the Anti-Migraine Drug Sumatriptan, 1992, Tetrahedron Lett. 33(52):8011-8014.
Remington's Pharmaceutical Sciences, Mack Pub. Co., Easton, PA (TOC).
Craig et al., Modern Pharmacology with Clinical Applications, 6thEd., Lippincott Williams & Wilkins, Philadelphia, pp. 639-656, 2004.
Hansen et al., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, 1989, J. Immunol. Methods 119:203-210.
Chawla-Sarkar, Preferential Induction of Apoptosis by Interferon (IFN)-β Compared with IFN-α2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines, 2001, Clin. Can. Res. 7:1821-1831.
Sun et al., Structure-based Design of Potent, Conformationally Constrained Smac Mimetics, 2004, J. Am. Chem. Soc. 126:16686-16687.
Park et al., Non-peptide small molecule inhibitors of XIAP, 2004, Bioorganic & Med. Chem. Lett. 15:771-775.
Lang's Handbook of Chemistry, Dean ed., Table 7-2, 1985.
Ambrosini et al., Induction of Apoptosis and Inhibition of Cell Proliferation by Surviving Gene Targeting, 1998, J. Biol. Chem. 273(18):11177-11182.
Chai et al., Structural and biochemical basis of apoptotic activation by Smac/DIABLO, 2000, Nature 406:855-862.
Zuckerman et al., Efficient Method for the Preparation of Peptoids [Oligo(N-substituted glycines)] by Submonomer Solid-Phase Synthesis, 1992, J. Am. Chem. Soc. 114:10646-10647.
Weinstein ed., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, 1983, Marcel Dekker, Inc., New York, New York (TOC).
Wyllie et al., Cell Death: the significance of apoptosis, 1980, Int. Rev. Cytol. 68:251-306.
Wyllie, Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation, 1981, Nature 284:555-556.
Fulda et al., Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo, 2002, Nat. Med. 8(8):808-815.
Deveraux et al., IAP family proteins-suppressors of apoptosis, 1999, Genes & Devel. 13:239-252.
Kasof et al., Livin, a Novel Inhibitor of Apoptosis Protein Family Member, 2001, J. Biol. Chem. 276(5):3238-3246.
Vucic et al., ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas, 2000, Curr. Biol. 10:1359-1366.
Ashhab et al., two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern, 2001, FEBS Lett. 495:56-60.
Du et al., Smac, a mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP lnhibitiion, 2000, Cell 102:33-42.
Verhagen et al., Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins, 2000, Cell 102:43-53.
Hay, Understanding IAP function and regulation: a view from Drosophila, 2000, Cell Death and Diff. 7:1045-1056.
Chan et al., Fmoc Solid Phase Peptide Synthesis: A Practical Approach, 2000, Oxford University Press (TOC).
Boxrud et al., Streptokinase Binds to Human Plasmin with High Affinity, Perturbs the Plasmin Active Site, and Induces Expression of a Substrate Recognition Exosite for Plasminogen, 2000, J. Biol. Chem. 275(19):14579-14589.
Owenius et al., Properties of Spin and Fluorescent Labels at a Receptor-Ligand Interface, 1999, Biophys. J. 77:2237-2250.
Hiratsuka, ATP-induced Opposite Changes in the Local Environments around Cys697(SH2) and Cys707(SH1) of the Myosin Motor Domain Revealed by the Prodan Fluorescence, 1999, J. Biol. Chem. 274(41):29156-29163.
Wu et al., Structural basis of IAP recognition by Smac/DIABLO, 2000, Nature 408:1008-1012.
Brunger, X-PLOR, a System for Crystallography and N
Condon Stephen M.
Deng Yijun
LaPorte Matthew G.
Rippin Susan R.
Banner & Witcoff , Ltd.
Tate Christopher R.
Teller Roy
Tetralogic Pharmaceuticals Corporation
LandOfFree
Dimeric IAP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dimeric IAP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dimeric IAP inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740500